Sugi Predict

Sugi Predict / Compounds / Ammonia Solution, Strong

Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL6001393

CCC(c1ccccc1F)c1ccccc1F.N

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 2/20 0.46
▸ TDO2 P48775 2/20 0.46
▸ GPR84 Q9NQS5 1/20 0.41
▸ CNR2 P34972 1/20 0.40
▸ TSHR P16473 1/20 0.39
▸ MC4R P32245 3/20 0.38
▸ CYP3A4 P08684 2/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ CES2 O00748 1/20 0.37
▸ CES1 P23141 1/20 0.37
▸ ACHE P22303 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ HTR2A P28223 1/20 0.37
▸ HRH1 P35367 1/20 0.37
▸ LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21910179 0.98 IDO1 (0.47) IDO1TDO2GPR84CNR2TSHR
SCHEMBL23159325 0.89 HRH1 (0.50) IDO1TDO2CNR2TSHRCYP3A4
SCHEMBL26693459 0.89 HRH1 (0.50) IDO1TDO2CNR2TSHRCYP3A4
SCHEMBL31469996 0.86 IDO1 (0.46) IDO1TDO2GPR84CNR2TSHR
Ammonia Solution, Strong SCHEMBL6001428 0.86 HTT (0.40) IDO1TDO2CYP3A4L3MBTL1MEN1
SCHEMBL25956070 0.82 IDO1 (0.40) IDO1TDO2CNR2TSHRCYP3A4
Ammonia Solution, Strong SCHEMBL6001224 0.82 IDO1 (0.42) IDO1TDO2CNR2ACHEMEN1
SCHEMBL781961 0.79 TSHR (0.40) IDO1TDO2CNR2TSHRMC4R
SCHEMBL20807370 0.77 TSHR (0.59) IDO1TDO2TSHRMC4RCYP3A4
SCHEMBL21138699 0.77 TSHR (0.59) IDO1TDO2TSHRMC4RCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060142594-A1 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases MUELLER ALAN L 2006-06-29 — — US disclosed
US-6750244-B2 NERVOUS SYSTEM DISORDERS NPS PHARMACEUTICALS, INC. 2004-06-15 — — US disclosed
US-6211245-B1 DRUGS FOR CONTROLLING CALCIUM MODULATORS NPS PHARMACEUTICALS, INC. 2001-04-03 — — US disclosed
US-6051610-A COMPOUNDS USEFUL AS NEUROPROTECTANTS, ANTICONVULSANTS, ANXIOLYTICS, ANALGESICS, MUSCLE RELAXANTS OR ADJUVANTS TO GENERAL ANESTHETICS NPS PHARMACEUTICALS, INC. (US) 2000-04-18 — — US disclosed
US-6017965-A TREATING STROKE, HEAD TRAUMA, SPINAL CORD INJURY, SPINAL CORD ISCHEMIA, ISCHEMIA- OR HYPOXIA-INDUCED NERVE CELL DAMAGE, EPILEPSY, ANXIETY, NEUROPSYCHIATRIC OR COGNITIVE DEFICITS DUE TO ISCHEMIA OR HYPOXIA NPS PHARMACEUTICALS, INC. (US) 2000-01-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142594-A1 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases NCS1, ATP2A1, CACNA1D IDO1 3661/4885TDO2 3085/4885GPR84 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.